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According to the World Health Organization, human
African trypanosomiasis (HAT) (sleeping sickness) caused
the loss of ≈1.5 million disability-adjusted life years
(DALYs) in 2002. We describe the effect of HAT during
2000–2002 in Buma, a rural community near Kinshasa in
the Democratic Republic of Congo. We used retrospective
questionnaire surveys to estimate HAT-related household
costs and DALYs. The HAT outbreak in Buma involved 57
patients and affected 47 (21%) households. The cost to
each household was equivalent to 5 months’ income for
that household. The total number of HAT-related DALYs
was 2,145, and interventions to control HAT averted 1,408
DALYs. The cost per DALY averted was US $17. Because
HAT has a serious economic effect on households and con-
trol interventions are cost-effective, considering only global
burden of disease rankings for resource allocation could
lead to misguided priority setting if applied without caution
in HAT-affected countries.
H
uman African trypanosomiasis (HAT), or sleeping
sickness, is a vectorborne disease caused by the para-
site Trypanosoma brucei. East African HAT, an acute syn-
drome, is caused by T. b. rhodesiense; West African HAT,
a disease with a more protracted course, by T. b. gambi-
ense. HAT is a major public health problem in sub-Saharan
Africa, where it affects mainly the rural poor; the most
recent prevalence estimates from the World Health
Organization (WHO) are 50,000–70,000 cases, based on a
total number of 17,500 new cases reported per year world-
wide (1). Odiit et al. calculated that 39% of HAT cases and
92% of deaths caused by HAT were unreported in a T. b.
rhodesiense –endemic area (2). In the absence of appropri-
ate treatment, HAT infection inevitably leads to death (2).
Although historic accounts of devastating epidemics exist
(3), the real effect of HAT on communities has not been
well documented.
WHO estimates that current HAT control activities
reach only 10% of persons at risk. HAT control requires
considerable resources, and budgets depend mainly on
international donors (4). Resource allocation by the latter
is often guided by criteria such as burden of disease
expressed in disability-adjusted life years (DALYs) as pro-
posed by Murray (5,6). This measure is the sum of years
lost due to premature death and years lost due to disabili-
ty. According to WHO global burden of disease estimates,
HAT caused 1.5 million DALYs in 2002 (7), which ranks
it much lower than most infectious diseases in Africa but
high among parasitic diseases. The use of DALYs for pri-
ority setting has provoked a lot of discussion, and caution
is needed when using them as a tool for planning and
resource allocation (8). The current estimate of HAT
DALYs is global and does not take into account local and
regional aspects. HAT has a clustered distribution, and at
times, local attack rates exceed 10%, but HAT is treated in
the same way as diseases that have relatively homoge-
neous attack rates (9). Moreover, differences in the course
of the disease caused by T. b. rhodesiense in East Africa
and that caused by T. b. gambiense in West and Central
Africa are ignored.
Another way to express the effect of the disease on
communities is to examine its economic effect at the house-
hold level (10). The advantage of this approach is that it can
enhance our understanding of how disease would cause fur-
ther impoverishment of the household and even hamper
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ic effects of HAT have been undertaken. Gouteux et al.
measured the days of productivity lost in Niari
(Brazzaville, Republic of Congo) and estimated the house-
hold cost to be 58,000 CFA francs (≈US $100) (11). These
authors suggested that this cost may have contributed to
patients’ frequently refusing to seek treatment, although
treatment is provided for free by the health services.
Despite the fact that almost all HAT control programs sub-
sidize the cost of drugs and hospitalization, often patients
either do not seek treatment or only do so a long time after
their diagnosis or when their symptoms become more acute
(12). Robays et al. showed how the enforced rest period of
6 months after treatment leads asymptomatic patients to
refuse treatment for fear of substantial loss of income (13). 
The indirect cost (i.e., all HAT-related costs incurred
by the household that are not for diagnosis, drugs, or care)
is a real obstacle that prevents persons from seeking treat-
ment (11). At a time when the world considers the fight
against poverty a top priority, we think that the practice of
setting priorities for healthcare based on aggregate figures
at the global level should be reexamined. We put forward
the hypothesis that neglected diseases such as HAT com-
promise the economic development and well-being of pop-
ulations in HAT-endemic regions to a much higher degree
than we are led to believe by lists of DALYs established
globally (14). The aim of our study was to document the
effect of HAT caused by T. b. gambiense during 2000–
2002 in a rural community in the Democratic Republic of
Congo (DRC) that was affected by a single outbreak.
Methods
Study Area
The study was conducted in the HAT focus of Buma,
in the N’sele health district in DRC, 35 km south of
Kinshasa. Buma consists of several villages, including
Buma-centre (population 1,000) and Kimpolo (population
300). The socioeconomic situation in each village is simi-
lar. Agriculture is the main economic activity and produces
maize, charcoal, firewood, vegetables, and leaves for
packaging of manioc. These products are sold in the mar-
kets of urban Kinshasa. 
The district medical officer of N’sele health district
declared the first suspected cases of HAT near Buma in
2000. The national program soon corroborated that health
facilities had been detecting HAT cases through passive
case finding and had been reporting cases from that area
for some time. In 2001, the control program sent a mobile
team to conduct an active case-finding campaign that was
repeated the following years. Screening in 2001 and 2002
confirmed 77 HAT cases in the Buma foci: 20 in Buma-
centre and 57 in Kimpolo.
Estimating Cost of Illness
All households of Buma and Kimpolo in which >1
HAT case was confirmed by the mobile teams or the per-
manent health facilities from January 1, 2001, through
December 31, 2002, were eligible. HAT was confirmed by
direct microscopic examination of lymph node aspirate,
fresh blood film, or thick blood film. In February 2003, we
identified all households with confirmed cases of HAT by
using a list provided by the village head, information pro-
vided by the inhabitants of Buma and Kimpolo, and data
from the epidemiologic surveillance of the Programme
National de Lutte contre la Trypanosomiase Humaine
Africaine (PNLTHA) in DRC. Households were visited to
ask members to participate in the study. The survey was
conducted after working hours and during the weekend by
3 enumerators trained by the principal investigator. A
pretested questionnaire was used for interviewing the
patients, their caregivers, or any other member of the
household who could provide useful information. All case-
patients in a household were interviewed. We collected
data on residence, age, sex, stage of the disease, number of
working days lost by the patient and caregiver, and expens-
es incurred because of HAT. For households with >1 case-
patient, the time of only 1 caregiver was taken into
account. Data on costs were collected in Congolese francs
(FC) and converted into US$ at the market rate for 2002,
which was 330 FC for 1 US$. The economic cost of HAT
comprises household costs and costs to the health system
minus transfers from the households to the health system,
to avoid double-counting. In this study, household costs
included consultation fees, cost of travel, laboratory costs
including all household expenses for diagnostic tests, and
the cost of hospitalization (all expenses for hospitalization
as well as food for the patient and caregiver). Treatment
costs included cost of drugs, injections, and small material
such as syringes and needles. The total cost of HAT for the
household was estimated as the sum of all costs mentioned
above and the value of all the days of work lost after HAT
confirmation. The value of each day of work lost was esti-
mated separately for each person, according to monthly
production of the household.
Estimating Household Monthly Income
Estimation of monthly household income was based
on agricultural production data. To validate this informa-
tion, these data were compared with household expenses
and financial aid received. Children’s production was con-
sidered to be zero even if the children helped with house-
hold tasks.
Because the main activity is agriculture and the work
in the fields is done by the whole family, quantifying the
contribution of the sick person to the household production
is difficult. In our calculations, we considered that the
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entire family’s activities are disturbed if 1 member is
affected by HAT. The income losses are calculated for
individual caregivers and patients and then examined as a
percentage of total household income.
Estimating DALYs
In August 2003, we organized a retrospective survey
of illness and death among all households of Buma-centre
and Kimpolo. Our objective for this second, exhaustive
household survey was to measure HAT-related DALYs for
confirmed HAT case-patients interviewed previously and
for other possibly nondetected HAT-related deaths in the
community that were missed by the control program. A
questionnaire was developed and pretested in Kimwenza,
another rural community near Kinshasa. We collected
information for a 3-year recall period, between 2000 and
2002. To help participants determine the recall period, we
constructed a local calendar with a number of key events,
including the attack of Tutsi rebels on the city in August
1998 and the death of president Laurent Désiré Kabila in
January 2001.
Ateam of 3 physicians visited all households of Buma
and Kimpolo to invite them to participate in the survey.
The head of the household or the person in charge was
interviewed. Information concerning residence, composi-
tion of the household, and economic activities was collect-
ed for each household. For each household member we
collected information about age, sex, and disease episodes
experienced during the recall period. The same informa-
tion was collected for household members who had died
between 2000 and 2002; verbal autopsies (caregiver inter-
views) were used to help determine the cause of death
(15). The interviewers used the following definition for a
HAT-related death: a person who died after a protracted
disease with loss of weight but without cough or diarrhea;
with repeated bouts of fever; and with or without neu-
ropsychiatric symptoms such as somnolence, psychosis,
and other behavioral problems. The patient record, if avail-
able, was examined to verify findings.
For each HAT case and HAT-related death, we docu-
mented the degree of disability caused by the disease
before, during, and after treatment. The degree of disabili-
ty was based on the scale proposed by Murray (5), for
which we adapted the list of activities for the Congolese
setting. To corroborate our interview results, we checked
other sources of information for illness and death in this
community, consulted administrative documents of the
neighborhood office, discussed with community leaders,
and visited 2 graveyards in Buma and Kimpolo to obtain
an exhaustive list of deaths and HAT cases.
Calculating DALYs
Calculations were based on the recommendations of
Murray (5). The total number of DALYs caused by a spe-
cific disease is defined as the sum of years lost by the pre-
mature death (years of life lost [YLL]) of patients and the
number of years lived with the disability (YLD) adjusted
for the severity of the disability. We used the calculation
method, discount rate of 0.03, age weighting factor of
0.04, and age weight modulating factor of 1 proposed by
Fox-Rushby and Hanson (16).
YLD for each patient was estimated from the ques-
tionnaire, and the results were combined to obtain the total
number of YLD. To estimate YLL, age categories spanning
5 years were used.
The life tables for each age group were estimated by
using Population Analysis Spreadsheets software
(International Programs Center, Bureau of the Census,
Washington, DC, USA). Data on age distribution, sex
ratio, and crude mortality rate were derived from the 2004
international database of the US Census Bureau (www.
census.gov/ipc/www/pas.html).
When these calculations are used, the number of
DALYs may be underestimated because of the poor sensi-
tivity of the active case-finding rounds (12,17). Our
exhaustive household survey and interviews with health
workers did not entirely correct for this bias because the
case definition used for verbal autopsy was specific and
mainly applied to patients with more advanced disease. We
tried to correct for this by supposing that each undetected
case-patient will eventually die. On the basis of observa-
tions of Robays et al., we estimated that the effectiveness
of the active case finding was 60% per round and that 40%
of the cases could not be detected (12).
Quantifying DALYs
We did an exhaustive census of DALYs caused by
HAT in 2 villages affected by the 2000–2002 outbreak. We
first used our observations to calculate DALYs caused by
HATin this community. Then we estimated DALYs caused
by HAT in absence of any intervention in the same com-
munity. To do this we needed to accept a number of
assumptions. On the basis of the work of Fèvre et al., we
estimated that without treatment the median survival time
for a person infected by T. b. gambiense is 36 months when
in the first stage of the HAT disease and 12 months when
in the second stage (18). The average degree of disability
of persons in the first or second stages of HAT was calcu-
lated by using the weightings developed by Murray et al.
(5) adapted to the DRC context. We compared the existing
intervention measures (active case finding followed by
treatment) to hypothetical nonintervention.
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We entered our data in an Access database (Microsoft
Corp., Redmond, WA, USA). Data were analyzed with
Excel (Microsoft Corporation) and EpiInfo 2002 (Centers
for Disease Control and Prevention, Atlanta, GA, USA).
Results
We found 47 households (21% of all households)
with >1 new HAT case diagnosed since 2000. We located
57 of the 77 HAT patients reported by PNLTHAin Buma-
centre and Kimpolo (74%) during 2000–2002. Four per-
sons died of HAT during this time in this community of
1,300 persons. Table 1 describes the household character-
istics. All but 1 patient eventually sought treatment after
varying time periods since diagnosis. Patient median age
was 26 years (range 4–72 years), and 57% of patients
were female. Fifty (87%) of the 57 cases were detected by
the mobile team during active case finding. At the time of
diagnosis, 36 (63%) were in the first stage of the disease.
The median time of patient hospitalization was 10 days
(range 7–45 days), and time after hospitalization (includ-
ing enforced rest) was 90 days (range 30–270 days); time
spent by caregiver during and after patient’s hospitaliza-
tion was 10 days (range 0–94 days). The percentages of
out-of-pocket expenditures incurred by the 47 households
in Buma for 57 HAT cases were as follows: indirect costs
94.55%, hospitalization 4.16%, treatment 1.11%, consul-
tation 0.10%, and laboratory 0.09%. The median value of
a day’s work per household was US $1.2. The median cost
of HAT case per household was US $163.98 (range
US $32.30–$3,731.70). This cost represents 43% of the
annual revenue of a household (an estimated US $384
[range US $0–$1,980]) and is based on agricultural pro-
duction and small trade.
An attempt to identify HAT cases from before 2000 by
using verbal autopsy and other methods was not success-
ful, most likely because this outbreak was recent. The
detailed evaluation of the total YLL caused by HAT is
shown in Tables 2 and 3. With and without intervention,
YLDs weighted for age would be 16 and 40, respectively,
and YLLs weighted for age would be 721 and 2,104,
respectively. A total of 2,145 DALYs (27 per case) would
have occurred in this community had no intervention taken
place. Under the current control strategy of repeated active
population screening and treatment, the disease still caused
737 DALYs. We conclude that the intervention enabled
1,408 DALYs to be averted at a savings of US $17 per
DALY. At a cost of US $301 for HAT control per case
detected and patient cured, the total intervention for 79.8
cases (57 cases detected multiplied by a factor of
1.4, assuming 40% of cases remain undetected) was
US $24,019.80.
Discussion
Our study shows that HAT costs households in Buma
the equivalent of 5 months of household income, despite
the fact that HAT control activities are heavily subsidized.
The cost for a patient with complications increases consid-
erably, to as much as 17 months of household income.
HAT complications concern mainly the central nervous
system; patients with this complication face a substantial
loss in productivity and, hence, revenue. The study shows
that a large number of working days were lost after treat-
ment for HAT, as the national program recommends a rest
period of 6 months. This recommended rest period is not
always adhered to exactly; some patients resume their
activities after 30 days, but others scrupulously rest for the
full period. This compulsory rest period contributes to the
fear of a HAT diagnosis.
Our survey involved a limited number of patients in a
rural district near the capital. Household incomes in more
isolated districts are probably lower than those in Buma,
and the effect of HAT on households is thus probably
greater. Another limitation of the study was that household
income was estimated on the basis of agricultural produc-
tion. This estimation was validated by the estimation based
on households’ real expenses. Seasonal variation of agri-
cultural production could affect our results. To better esti-
mate loss of production, a prospective study comparing
households with and without HAT would be necessary
because the disease is chronic and weakens the household
progressively.
Our figures are comparable to those of Gouteux et al.,
who calculated the average household cost of a HAT
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finding funds to meet health expenses for HAT has been
reported by Odiit et al. (19). Household cost studies have
shown that rural populations are often incapable of finding
the funds to make even small, symbolic payments for
healthcare and disease prevention. In Kenya, households
were not able to pay for an impregnated bed net, even at a
reduced price (20). Poor households in Malawi required
32% of their income to cover expenses linked to malaria
(21). In Tanzania, the household cost for tuberculosis (in
addition to the cost of treatment [US $20]) varied between
US $187 and US $1,457 (22).
Ours is 1 of few studies to analyze the economic effect
of HAT at the household level. This aspect is rarely cap-
tured by public health analyses, which often remain at the
level of quantifying illness and death. The socioeconomic
effect of a severe disease such as HAT goes beyond these
figures. During our study in Kimpolo, farmers told us how
in the year 2000 they slaughtered all their pigs after the
first cases of HAT were identified because a community
health worker had advised them to do so to decrease the
density of tsetse flies.
This study estimated that HAT would have caused
2,145 DALYs in the absence of intervention. The interven-
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DALYs at a cost of US $17 per DALY averted. These fig-
ures were based on a number of assumptions. When quan-
tifying DALYs, we assumed that a patient would die after
a median of 3 years (18). We also assumed, according to
the work of Robays et al., that 40% of the real HAT cases
remain undetected by 1 screening round and that these
case-patients would inevitably die (12). However, in prac-
tice, these persons could be detected subsequently at fixed
health facilities or during a second visit by a mobile team.
The cost of the intervention per DALY averted falls with-
in the ranges modeled by Shaw and Cattand (23). The US
$17 cost per DALY averted is lower than for many health
interventions (e.g., the cost per DALY of US $19–$85 for
insecticide-treated bed nets for malaria control in sub-
Saharan Africa) and places HAT control in the range of
cost-effective interventions (24,25).
Nevertheless, the cost of treatment borne by house-
holds is considerable and can compromise the timely
receipt of treatment. Household members take time to pre-
pare themselves and mobilize resources, relying on the sol-
idarity of the extended family, before they seek treatment
for HAT. The high household cost may partly explain the
low participation rate at the active screening session organ-
ized by the mobile teams (12).
We conclude that not only does HAT affect the health
of the persons touched by the disease, but also it places a
substantial hardship on the affected households. This effect
can be fully evaluated only when taking into account spe-
cific local situations. Using a global DALYs ranking to set
healthcare priorities may not capture the full effect of cer-
tain diseases in communities. 
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